Purpose: To assess mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years' treatment with aflibercept in a real-life setting. Methods: This was an observational cohort study using nationwide data from the Swedish Macula Register. Treatment-na€ ıve patient eyes with wet age-related macular degeneration and prescribed aflibercept from January 2013 to December 2014 were followed for 1 year (2478 eyes) or 2 years (831 eyes) to assess VA. Eyes were grouped by baseline VA. Results: Mean number of injections in patients treated according to label (72%) versus patients treated not according to label was 8.0 AE 1.5 versus 4.4 AE 0.8 (p < 0.0001) at 1 year, and 12.5 AE 3.2 versus 7.3 AE 1.9 (p < 0.0001) at 2 years. Among all eyes, mean VA increased from 61.3 AE 13.4 Early Treatment Diabetic Retinopathy Study letters at baseline to 64.5 AE 15.6 at 1 year and 65.1 AE 15.1 letters at 2 years. At 2 years, eyes with good baseline vision (≥70 letters) lost a mean of 2.4 AE 11.3 to 72.3 letters, eyes with intermediate baseline VA (36-69 letters) gained 5.7 AE 14.1 to 62.7 letters, and eyes with poor baseline VA (≤35 letters) gained 13.2 AE 18.3 to 41.0 letters. Also at 2 years, 75% of treated eyes were stable or had improved VA. Among eyes with intermediate baseline VA, near vision was significantly better among those treated according to label versus not according to label at 3 (p = 0.019), 6 (p = 0.0002) and 12 months (p ≤ 0.0001). Conclusion: While gain in vision was especially pronounced in eyes with poor baseline VA, good baseline VA was important for best prognosis.
Introduction
Antivascular endothelial growth factor (anti-VEGF) therapies, such as aflibercept and ranibizumab, have been shown to be efficacious in improving and maintaining visual acuity (VA) in neovascular age-related macular degeneration (AMD) and all subtypes of choroidal neovascularization secondary to AMD when given in a timely manner (Freund et al. 2013; Tah et al. 2015) . The use of such treatments is steadily increasing worldwide. While both aflibercept and ranibizumab have shown to provide good visual outcomes after 2 years' treatment in clinical trials (Rosenfeld et al. 2006; Schmidt-Erfurth et al. 2014) , realworld evidence has been less consistent. In a recent observational study of ranibizumab in several European countries, improvement in VA after the first three injections was not maintained, likely owing to less frequent injections and undertreatment of patients in realworld clinical practice compared with the approved treatment schedule (Holz et al. 2015) . Similar findings were seen among ranibizumab treated real-world wet AMD patients in Sweden after 3 years of treatment over recent time periods (Rung & Lovestam-Adrian 2013; Schroeder et al. 2017) .
In an observational study of patients with wet AMD identified from the Swedish Macular Register (SMR, 2011 (SMR, -2014 , Westborg et al. concluded that, in the line with previous studies, improvements in VA over the years were seen for all patients at baseline and after 1 year of anti-VEGF therapy, while the mean change in VA observed after the first treatment year remained stable for the majority of patients irrespective of baseline VA (Westborg et al. 2017) . Furthermore, evidence suggests that poor baseline VA [24-34 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] is a predictor of maximum gain in VA, but eyes with better baseline VA (55 letters) have better final VA (Bloch et al. 2013; Westborg et al. 2017) . The importance of baseline VA on VA gain has also been addressed by others (Gillies et al. 2015) . Although Westborg et al. (2017) did evaluate different treatment regimens -aflibercept, bevacizumab and ranibizumab, real-world evidence on treatment outcomes in eyes with variable baseline VA is sparse in patients treated with aflibercept, as is an evaluation of effects of treatment given according to the aflibercept label versus not according to label. The aim of our observational cohort study was to describe characteristics of patients with wet AMD treated with aflibercept identified from the SMR, with a focus on the mean change in VA after 1 and 2 years' treatment, both overall (all eyes) and stratified by baseline VA.
Materials and Methods
The Impact of baseliNe viSual acuity on the treatment outcomes in patients treated with AflIbercept in real-life clinical settinG, analysis of data from the SwedisH Macula RegisTer (INSIGHT) study was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the Lund University Ethical Board. Data were obtained from the SMR after approval from its steering committee.
Data source and study population
The Swedish Macula Register (SMR), a national quality register, in 2008 started collecting information about treatment of choroidal neovascularization with intravitreal injections. The register is funded by the Swedish Association of Local Authorities and Regions, and the Swedish government collects data from patients treated for choroidal neovascularization from most medical centres across Sweden for both quality improvement and research purposes. Neovascular AMD represents 97% of all diagnoses registered in the SMR. Between 2008 and 2015, a total of 21 572 patients with neovascular AMD were registered (Westborg et al. 2017) .
In 2015, around 1.6% of the Swedish general population (aged ≥70 years) were included in the registry. In 2016, 40/41 eye clinics nationwide were using the SMR; national coverage of treatments and follow-up visits is around 80%, which means that approximately 80% of all patients in Sweden treated for wet AMD have records in the SMR. These calculations are based on a comparison with a nationwide patient-diagnosis register where all patients with diagnosed AMD with an indication for intravitreal injection are included. Patients' eyes were included in the study if they were treatment na€ ıve and had wet AMD treated with aflibercept as first anti-VEGF therapy. The study considered either one or two eyes per patient.
Study variables and follow-up
All study data were extracted from patients' electronic records in the SMR. Baseline data were collected from 1 January 2013 to 31 December 2014. The baseline visit was the first visit at which wet AMD was diagnosed and treatment was prescribed if this was administered within 1 week. Data were obtained on patients' sex, age, presenting symptoms (self-reported symptoms connected to wet AMD that caused the patient to consult an ophthalmologist, i.e. metamorphopsia, reduced VA, problems with reading), macular lesion type, VA of the treated eye measured with the Snellen and ETDRS charts, near VA of the treated eye, best or worse seeing eye, total number of received injections, treatment regimen (according to label, yes/no) and adverse events (AEs). Where VA had been measured using the Snellen chart, it was converted into ETDRS VA, according to Gregori et al. (2010) . Early Treatment Diabetic Retinopathy Study (ETDRS) VA was registered in around 80% of the visits at baseline and at 87% at 1-year follow-up. Visual acuity of hand movements and amaurosis was converted into ETDRS 0.001. Near VA, LIX is a readability measure indicating the difficulty of reading a text and was measured using the Jaeger chart at approximately 35 cm distance and addition of +3.0 to bestcorrected VA. Treated eyes were stratified into three groups according to baseline VA: group 1 with good baseline vision, ≥70 letters (0.5); group 2 with intermediate baseline vision, 36-69 letters; group 3 with poor baseline vision, ≤35 letters (0.1). Treatment exposure was ascertained by month/year and split by better/worse seeing eye, year and baseline VA group. Follow-up was stratified into 10-14 months (~1 year) or 22-26 months (~2 years). The study end date was 31 December 2016.
Outcomes
Outcomes were assessed for all eyes and stratified by baseline VA group. These included mean change in VA (Snellen), ETDRS and LIX at 3 AE 1 months, 12 AE 2 months and 24 AE 2 months follow-up (reported in typographical points, range 4-24 points); the proportion of patients with one of five VA outcomes: gain in vision (5 to 15 letters or >15 letters), loss of vision (>5 to <15 letters or >15 letters) or stable (À5 to +5 letters) at 1 and 2 years; and the number of aflibercept injections at 1 and 2 years stratified by better/worse seeing eye. The number of patients receiving treatment according to the aflibercept label was also evaluated -this was defined as having the first three injections within 3 months (120 days) and a total of 6-7 injections during the first year. Patients who received aflibercept treatment that did not satisfy these criteria were considered as treated not according to label. Other outcomes were VA at 1 and 2 years stratified by treatment according to label (yes/no), near VA, the proportion of patients that recuperated 20/20 vision and 20/40 vision (driving vision), and the proportion requiring no need for vision aid support. Adverse events (AEs) were also assessed.
Statistical analysis
Baseline characteristics and study outcomes were summarized for all eyes and stratified by baseline VA group. Data were described using mean, median, 1st and 3rd quartile, standard deviation and range for continuous variables, and frequency counts and percentages for categorical variables. Comparisons between two groups for VA were based on Student's t-test. Wilcoxon rank sum test was used when nonparametric values were analysed, that is for near VA. Analysis of variance (ANOVA) was used to compare the number of injections between outcome groups' gain in vision, and if statistically significant, pairwise comparison between the groups was made using Student's t-test. Associations between VA and age, membrane type, baseline VA and number of injections were evaluated using linear regression methods. The percentage of patients eligible for low vision support at 1 and 2 years' follow-up was also determined [in Sweden, these are patients with vision <0.3 Snellen (60 letters ETDRS) in their best eye]. Statistical significance was assumed at the p-value <0.05 level.
Results

Baseline characteristics
A total of 2478 eyes in 2312 patients were included and followed for 1 year, and 831 eyes in 794 patients were followed for 2 years. Baseline characteristics of all eyes are shown in Table 1 ; VA was good in 786 eyes, intermediate in 1573 eyes and poor in 119 eyes. Among eyes followed for 2 years, the number in the good, intermediate and poor baseline VA groups (i.e. groups 1, 2 and 3) were 282, 519 and 30 eyes, respectively. Mean age was 78.5 AE 8.0 years, and 67% of eyes were from females; no differences in sex distribution were seen between the three baseline VA groups. Group 1 were on average, younger than group 2 (p < 0.0001) and group 3 (p < 0.0001). Of all eyes, symptom duration before treatment start was <2 months in 45% and >6 months in 17%. Group 1 had the highest proportion of eyes (51%) where symptom duration was <2 months. Lesions were diagnosed and classified in 83% of eyes as follows; 1-49% classical in 6%, 50-100% classical in 18%, 100% occult in 40%, polypoidal choroidal vasculopathy in 3% and retinal angiomatous proliferation in 16%. Around 38% of patients also had some sort of maculopathy registered for the second eye. Of eyes in group 1, 48% were diagnosed with occult membrane and 19% had classical lesion, while quite the opposite was observed among patients in group 3, 24% and 34%, respectively. Seventeen per cent of patients were in need of vision aid support at baseline, the majority (54%) being in group 3 (none were in group 1). (70) 144 (70) 548 (70) 743 (65) 300 (69) 1043 (66) 36 (58) 37 (65) 73 (61) 1183 (66) 481 (69) 1664 (67) Symptom duration 0-<2 months 290 (50) 109 (53) 399 (51) 489 (43) 179 (41) 668 (42) 26 (42) 24 (42) 50 (42) 805 (45) 312 (45) 117 (45) 2-<4 months 134 (23) 40 (20) 174 (22) 282 (25) 104 (24) 386 (25) 17 (27) 11 (19) 28 (24) 433 (24) 155 (22) 588 (24) 4-6 months 76 (13) 16 (8) 92 (12) 174 (15) 62 (14) 236 (15) 9 (15) 10 (18) 19 (16) 259 (15) 88 (13) 347 (14) >6 months 81 (14) 40 (20) 121 (15) 191 (17) 92 (21) 283 (18) 10 (16) 12 (21) 22 (18) 282 (16) 144 (21) 426 (17) Type of lesion 1-49% classical 29 (5) 11 (5) 140 (5) 86 (8) 28 (6) 114 (7) 6 (10) 1 (2) 7 (6) 121 (7) 40 (6) 161 (6) 50-100% classical 81 (14) 30 (15) 111 (14) 226 (20) 83 (19) 309 (20) 17 (27) 16 (28) 33 (28) 324 (18) 129 (18) 453 (18) Occult (%) 295 (51) 84 (41) 379 (48) 441 (39) 153 (35) 594 (48) 16 (26) 12 (21) 28 (24) 752 (42) 249 (36) 1001 (40) PCV (%) 12 (2) 11 (5) 23 (3) 35 (3) 22 (5) 23 (3) 3 (5) 3 (5) 6 (5) 50 (3) 36 (5) 86 (3) RAP (%) 92 (16) 32 (16) 124 (16) 189 (17) 64 (15) 253 (16) 9 (15) 7 (12) 16 (13) 290 (16) 103 (15) 393 (16) Not known (%)
72 (12) 37 (18) 109 (14) 159 (14) 87 (20) 246 (16) 11 (18) 57 (32) 29 (24) 242 (14) 142 (20) 384 ( Injections 1779/2478 eyes (72%) were treated according to label. At 3 months, the mean number of injections among patients treated according to label versus not according to label was 3.4 AE 0.5 versus 2.5 AE 0.8; p < 0.0001, and at 1 year, it was 8.0 AE 1.5 versus 4.4 AE 0.8 injections; p < 0.0001. Among 831 eyes followed for 2 years, 716 (86%) were treated according to label in the first year and had received a total of 12.5 AE 3.2 injections after 2 years, whereas the treated not according to label group had received 7.3 AE 1.9 injections; p < 0.0001 at this time-point. The number of injections for all eyes followed for 1 year was higher in group 1 compared with group 3: 7.2 AE 2.2 versus 6.3 AE 2.1 injections; p < 0.0001. The same tendency was shown for eyes followed for 2 years; 12.6 AE 3.3 versus 9.9 AE 3.4 injections; p < 0.0017.
Mean change in visual acuity
Among all eyes, VA increased from 61.3 AE 13.4 letters at baseline to 65.5 AE 13.3 letters at 3 months, 66.4 AE 13.5 letters at 6 months, 64.5 AE 15.6 letters at 12 months and 65.1 AE 15.1 letters at 2 years. After 3 months (1365 eyes), VA in group 1 was stable, whereas groups 2 and 3 gained 5.4 AE 10 letters and 15.0 AE 16.6 letters, respectively. At 12 months, group 1 had dropped 0.9 AE 10.4 letters compared with baseline, whereas group 2 gained 4.4 AE 13.6 letters and group 3 gained 15.6 AE 18.3 letters. Maximum gain of vision was seen in group 3 after 6 months, with a gain of 17.0 AE 15.7 letters. At 24 months (831 eyes), group 1 (268 eyes) lost 2.4 AE 11.3 letters, group 2 (504 eyes) gained 5.7 AE 14.1 letters and group 3 (29 eyes) gained 13.2 AE 18.3 letters. Change in VA, stratified by baseline VA and treatment according to label (yes/no) at 1 year (n = 2478 eyes) and 2 years (n = 831 eyes), is shown in Fig. 1 .
Visual acuity and treatment regimen
Visual acuity, stratified by baseline VA and by treatment according to label/ not according to label at 1 and 2 years, is shown in Fig. 2 . Patients will be considered as treated according to label if they received three initial injections within 3 months (120 days) and a total number of 6-7 injections during the first year. Patients who received treatment that did not satisfy these criteria were considered as treated not according to label. At 1 year, treatment according to label had a positive impact on VA in all baseline VA groups, particularly in group 2; mean VA in eyes treated according to label and not according to label was 74.3 AE 10.8 versus 73.5 AE 10.7 letters (p = 0.3588) in group 1, 62.4 AE 13.9 versus 58.7 AE 16.4 letters, p < 0.0001 in group 2 and 45.7 AE 17.0 versus 41.5 AE 15.4 letters p < 0.1599 in group 3. In eyes followed for 2 years, there was no evidence of a difference in mean VA in eyes treated according to label/not according to label in any baseline VA group. Visual acuity at 2 years in eyes in treated according to label versus not according to label was 72.8 AE 10.5 versus 69.4 AE 14.5 letters (p = 0.1587). Corresponding figures for group 2 were 62.9 AE 14.4 versus 61.9 AE 15.2 (p = 0.3042), and corresponding figures for group 3 were 43.8 AE 14.9 versus 33.8 AE 27.3 (p = 0.3498) (Fig. 1) . It should be noted that only 14% of the 831 eyes that were treated not according to label were followed for 2 years. 
Better and worse seeing eye
About 1264/2478 eyes (51.0%) in the study were the patients' better eye. After both 1 and 2 years' follow-up, there was no difference in the number of injections given if the eye treated was the better or worse eye; 7.1 AE 2.1 and 11.9 AE 3.7 injections, respectively. A difference in change in VA at 1 and 2 years between better/worse seeing eye was only observed for group 2 (p = 0.0002), who showed an increase in gained letters for the worse seeing eyes (7.9 AE 15.1 letters) compared with 3.3 AE 12.4 letters for the better-seeing eyes.
Proportion of eyes with a gain in vision
In all groups, around 80% of eyes remained stable or improved in VA after 1 year. Gain in vision was most pronounced in group 3, where 42% gained more than >15 letters. At 2 years, VA remained stable or improved in the majority of eyes (75% in group 1 and around 85% in groups 2 and 3). The proportion of eyes with a gain in vision, stratified by baseline VA group and treatment by label/not according to label, is shown in Fig. 3A for outcome at 1 year and Fig. 3B for outcome at 2 years. At 1 year, mean number of injections was 6.2 AE 2.1 among the outcome group with a loss of >15 letters, while among other outcomes groups, this was much higher (p < 0.0001, ANOVA). The corresponding number at 2 years was 11.0 AE 3.3 for the loss of >15 letters outcome group, again being higher among the other outcome groups (p = 0.0277).
Near visual acuity and gain in vision
Near VA, stratified by baseline VA and by treatment according to label/not according to label at 1 year (1859 eyes) and 2 years (515 eyes), is shown in Fig. 4 . Near VA in group 1 was stable at all time-points. In group 2, eyes treated according to label versus not according to label improved À3.0 AE 5.5 versus 1.5 AE 5.6 (p = 0.019) at 3 months; À3.4 AE 6.0 versus À1.3 AE 5.5 points (p = 0.0002) at 6 months and À3.4 AE 6.5 versus À1. 
Low vision support, predictors of VA and AEs
Fifteen per cent of patients qualified for vision support at 1 year of followup (2% fewer than at baseline); in group 3, half of patients were eligible for vision support compared with only 4% in group 1. A significant impact on VA outcome was seen for age, baseline VA and number of injections (p < 0.0001 for all), while membrane type was not associated with VA. Adverse events were observed in 86/2478 eyes (3.47%) followed for 1 year and 19/831 eyes (5.05%) followed for 2 years. The most common complications during the first year were pigment epithelium tear (1.49%) and corneal complications (1.21%) (Tables 2 and 3 ).
Discussion
In this large population-based study in Sweden, we followed patients with wet AMD receiving aflibercept as first anti-VEGF treatment in clinical practice for up to 2 years to evaluate visual outcomes. We observed that patients with the lowest baseline VA also had the most pronounced gain in VA, a finding described previously by others (CazetSupervielle et al. 2015; Gillies et al. 2015) . Our study builds upon previous research using the SMR (Westborg et al. 2017) , which found that visual outcome after 1 year of anti-VEGF therapy has increased in recent years, and that this was because of a higher baseline VA. We also observed that 72% of the patients were treated according to label and had received approximately 12 injections after 2 years' treatment. This is a more encouraging finding than that observed in previous studies from clinical practice in Sweden (Rung & LovestamAdrian 2013; Schroeder et al. 2017; Westborg et al. 2017 ) and other countries (Holz et al. 2015) . In our study, most eyes had an intermediate VA at baseline followed by the best seeing group, whereas only 5% started with a poor VA. This distribution in baseline VA is in concordance with a study by Gillies et al. (2015) . We additionally observed that patients with the lowest baseline VA also had the most pronounced gain in VA, something that has been described previously (CazetSupervielle et al. 2015; Gillies et al. 2015) . When comparing visual outcome in eyes treated according to label or not, a difference was seen among eyes with intermediate vision at baseline, which had a better VA outcome after 1 year. This was the largest group, including 63% of eyes in the study -just over 30% had good baseline VA and only 5% had poor VA at baseline -a distribution concordant with that seen by Gillies et al. (2015) . However, at 2 years' follow-up, no difference was seen between eyes treated according to label/not according to label in any baseline VA group. This was unexpected, but might have been because only 14% of the 831 eyes that were treated not according to label were followed for 2 years. Near vision, as expressed by reading index Lix, has been shown to be a very sensible vision and reading parameter (Epstein & Amren 2016) . In this present study, we found that near vision was significantly better in eyes treated according to label in patients with intermediate baseline VA at 3, 6 and 12 months' follow-up. This is important because near vision reflects the patient's ability to read near text, for example in newspapers, and is therefore informative of how treatment might influence patients' daily life.
Interestingly, although the number of injections was higher in those with good rather than poor baseline vision for all eyes followed for 1 or 2 years, the latter group actually gained the most letters. A ceiling effect when starting at a high baseline VA level has been reported before (Gillies et al. 2015; Talks et al. 2016) Fig. 4 . Near vision (points) at 3, 6, 12 and 24 months stratified by baseline VA group and by treatment regimen (label/not according to label). Note, there were no eyes treated not according to label left in the study in group 3 at 24 months. Not label = not according to label. patients receiving slightly fewer injections (n = 6) than those in our study (n = 7). Thus, it might be that maintaining VA when starting treatment at a high baseline VA could be achieved with less frequent injections. In Sweden, recent years have seen an increasing number of clinics using a treat-and-extend regimen, which has resulted in an increasing number of injections given and has shown to be noninferior to treatment every other month (Haga et al. 2018) . That a switch from a pro re nata regimen (i.e. reactive treatment when needed) to a treat-and-extend regimen (proactive treatment with extending intervals) could generate more injections has been shown by others (Oubraham et al. 2011; Kvannli & Krohn 2017) . For a good visual outcome, however, baseline VA seems to be the most important factor and more important than the frequency of injections, something that was also found in a post hoc analysis of the View studies (Lanzetta et al. 2018) . As expected we also found that a better baseline VA was associated with shorter symptom duration, something that investigated in a study in Denmark, which found that shorter symptom duration was beneficial for a better visual outcome (Rasmussen et al. 2015) , and in another study that found the time to first injection to be predictive even after controlling for age, sex and baseline VA (Lim et al. 2012) . This further emphasizes the importance of early diagnosis and treatment.
Our results show that as many as 80% of eyes in the study remained stable or improved in all treatment groups at 1 year and 75% at 2 years' follow-up. These are lower percentages than seen in the View study (SchmidtErfurth et al. 2014) , where around 90% were stable after 2 years; however, the definition of maintaining VA was <15 letters loss, whereas it was defined as <5 letters loss in our study. Thus, even in the group that start with poor baseline VA, and where outcome VA is expected to be low, treatment is still worthwhile because they often gain many letters and stabilize at a higher level than before.
It is known that several factors are important for a good visual outcome among patients with wet AMD. In agreement with other studies (Finger et al. 2014; Ying et al. 2015) , we observed that younger patients, better baseline VA and increasing number of injections had a significant impact on visual outcome. Reports have also identified different sort of lesions as having an impact on VA outcome (Ying et al. 2015) , something that was not confirmed in this study. Over recent years, there has been a decline in specifying the type of lesion in the SMR in favour of entering this variable as 'not known' (15% of lesions were recorded as unknown type in our present study). This is likely owing to the rectifying of treatment options, which might cause inferior interest and skill in diagnostics. We also showed that as many as 83% in the best baseline vision group and 42% in the intermediate group were allowed to drive after 1 year of treatment compared with only 8% in the lowest vision group. Even though patients are elderly, having a driving licence is still an issue for many. Few AEs occurred, and the proportion of endophthalmitis was around 0.12%, which is in parity with other studies, but retinal pigment epithelial tear was higher compared with other studies (Schmidt-Erfurth et al. 2014) .
Strengths of this study include its description of visual outcomes among patients with wet AMD starting treatment with aflibercept in real-world clinical practice, using a macular register covering around 80% of the treated wet AMD patient population in Sweden. Limitations include the fact that management of patients with wet AMD may differ between clinics across Sweden and that participation in the SMR is voluntary. In addition, patients may have discontinued treatment prior to the 1-and 2-year follow-up endpoints, and this may have caused some selection bias when comparing baseline VA groups; for example, if discontinuers differed from those who adhered to treatment and the proportion of discontinuers differed between baseline VA groups. Misclassification of baseline and outcome VA is also possible in cases where ETDRS values were converted from Snellen values, any errors being most notable at low vision values.
In conclusion, these real-world data from Sweden showed that 75% of the eyes treated with aflibercept for wet AMD improved or remained stable at 2 years' follow-up and that most patients had received injections according to label. Although gain in vision was more pronounced in eyes with poor baseline VA, good baseline VA was an important prognostic factor for a good VA outcome. Thus, an early diagnosis and treatment of AMD are of most importance. 
